SPRY
ARS Pharmaceuticals, Inc.
There isn't enough reported data to score SPRY yet.
SPRY Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
SPRY's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
SPRY PE Valuation
SPRY has no meaningful PE right now: it lost money over the past year.
SPRY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect SPRY's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
SPRY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.01 | -$1.20 |
| Q2 2026 | -$2.17 | -$1.68 |
| Q1 2026 | -$2.00 | -$1.84 |
| Q4 2025 | -$1.74 | -2275% |
| Q3 2025 | -$0.81 | -$0.30 |
| Q2 2025 | -$0.49 | -$0.02 |
| Q1 2025 | -$0.16 | +$0.36 |
| Q4 2024 | $0.08 | +$0.65 |
SPRY is still losing money, but less than at its worst: $2.01 per share over the past year, against $2.72 at its worst in early 2022.
SPRY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.7M | +16% |
| Q2 2026 | $33.7M | +114% |
| Q1 2026 | $22.7M | +184% |
| Q4 2025 | $28.1M | -68% |
| Q3 2025 | $32.5M | +1472% |
| Q2 2025 | $15.7M | +3043% |
| Q2 2024 | $500K | +4900% |
SPRY's revenue is recovering but still below its 2024 peak: $38M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -91% | +73 points |
| Q2 2026 | -183% | +120 points |
| Q1 2026 | -265% | +201 points |
| Q4 2025 | -148% | -202 points |
| Q3 2025 | -164% | +888 points |
| Q2 2025 | -303% | +2765 points |
| Q1 2025 | -466% | N/A |
| Q4 2024 | 55% | N/A |
SPRY's operating margin was −91% last quarter, up 73 points from the same quarter a year ago.
SPRY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$33.7M | +$13.5M |
| Q2 2026 | -$60.9M | -$21.3M |
| Q1 2026 | -$44.9M | -$4.1M |
| Q4 2025 | -$43.5M | -204% |
| Q3 2025 | -$47.2M | -$32.6M |
| Q2 2025 | -$39.6M | -$32.3M |
| Q1 2025 | -$40.8M | -$34M |
| Q4 2024 | $41.7M | +$59M |
SPRY has burned cash in almost every quarter: −$183M over the past year, against −$86M the year before.
SPRY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +373K shares |
| 1 year | +0.9% | +878K shares |
| 3 years | +4.3% | +4.1M shares |
| 5 years | +186% | +64.8M shares |
| Available history | +201% | +66.6M shares |
SPRY has 100M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
SPRY Net Leverage
SPRY's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SPRY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 14.3 | Oversold |
SPRY's weekly RSI is 36 (neutral) and its Stochastic is 14 (oversold).
SPRY PE vs Healthcare Sector
| Metric | SPRY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SPRY has no meaningful PE right now: it lost money over the past year.
SPRY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.80 | 0.3% above |
| 20 week MA | $5.13 | 26% below |
| 50 week MA | $7.64 | 50% below |
| 100 week MA | $10.2 | 63% below |
| 200 week MA | $9.31 | 59% below |
SPRY has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 59% below its 200-week average.
SPRY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.0 | $35.8 | +43% |
| 2021 | $35.8 | $6.65 | -81% |
| 2022 | $6.65 | $8.08 | +22% |
| 2023 | $8.08 | $5.48 | -32% |
| 2024 | $5.48 | $10.8 | +97% |
| 2025 | $10.8 | $11.4 | +5.5% |
| 2026 YTD | $11.4 | $3.81 | -67% |
SPRY is down 67% so far in 2026, after finishing higher in four of the previous six years.